Search

Your search keyword '"MacConell L."' showing total 175 results

Search Constraints

Start Over You searched for: Author "MacConell L." Remove constraint Author: "MacConell L."
175 results on '"MacConell L."'

Search Results

1. A43 LONG-TERM EFFICACY AND SAFETY OF OBETICHOCLIC ACID IN PRIMARY BILIARY CHOLANGITIS: RESPONDER ANALYSIS OF OVER 5 YEARS OF TREATMENT IN THE POISE TRIAL

2. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients

3. Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis

4. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years

5. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials

7. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

9. A217 NONINVASIVE ASSESSMENTS TO IDENTIFY PATIENTS WITH ADVANCED FIBROSIS DUE TO NASH: SCREENED POPULATION FROM THE REGENERATE TRIAL

12. Obeticholic Acid Efficacy in Patients With NASH Monitored Using Noninvasive Tests: Post Hoc Analysis of REGENERATE Trial

13. T06.01.12 OBETICHOLIC ACID (OCA) IMPROVES NON-INVASIVE MARKERS OF FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH): A SECONDARY ANALYSIS OF THE PHASE 3 REGENERATE STUDY

14. OC.05.5 OBETICHOLIC ACID TREATMENT IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: A SECONDARY ANALYSIS OF THE REGENERATE STUDY ACROSS FIBROSIS STAGES

15. Durable response in the markers of cholestasis through 5 years of open-label extension study of obeticholic acid in primary biliary cholangitis

16. Obeticholic Acid Treatment in Patients with Non-Alcoholic Steatohepatitis: A Secondary Analysis of the Regenerate Study Across Fibrosis Stages

20. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study

21. Langzeitbehandlung mit Obeticholsäure ist bei Patienten mit Primär Biliärer Cholangitis mit Verbesserungen der Kollagen-Morphometrie assoziiert

22. OC.01.4 THREE YEARS OF OBETICHOLIC ACID (OCA) THERAPY RESULTS IN HISTOLOGICAL IMPROVEMENTS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: FURTHER ANALYSIS OF THE POISE BIOPSY SUBSTUDY

23. Three years of obeticholic Acid (OCA) therapy results in histological improvements in patients with primary biliary cholangitis: further analysis of the POISE Biopsy substudy

24. Three years of Obeticholic Acid (OCA) Therapy Results in Histological Improvements in Patients with Primary Biliary Cholangitis: Further Analysis of the POISE Biopsy Substudy

25. Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis

27. Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC)

32. PC.01.8 THE AESOP TRIAL: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS

35. Obeticholic acid (OCA) improves non-invasive markers of fibrosis in patients with non-alcoholic steatohepatitis (NASH): a secondary analysis of the phase 3 Regenerate study

43. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

44. Durable response in the markers of cholestasis through 18 months of open-label extension with obeticholic acid in primary biliary cholangitis

50. A Multicenter, Randomized, Open Label, Single- and Multiple-Dose, Dose Finding Study and Open-Label Extension to Assess the Effects of Obeticholic Acid in Pediatric Patients with Biliary Atresia

Catalog

Books, media, physical & digital resources